GlassScriptPhysician profile
Jubran Hoche
NPI 1710174362
$2,994.36
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2020: $441 · 2021: $1,208 · 2022: $825 · 2023: $66.18 · 2024: $17.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $83.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $83.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $538.90 | 2021-2023 | |
| Amgen INC. | $507.83 | 2021-2022 | |
| Ucb, INC. | $265.49 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $186.10 | 2019-2022 | |
| Mdd US Operations, LLC | $164.92 | 2019 | |
| Genzyme Corporation | $156.46 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $150.22 | 2019-2022 | |
| Allergan, INC. | $144.61 | 2020 | |
| Janssen Pharmaceuticals, INC | $106.00 | 2021-2022 | |
| Eisai INC. | $105.64 | 2020-2021 | |
| Lundbeck LLC | $74.62 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $65.78 | 2021 | |
| Lilly USA, LLC | $60.24 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $56.17 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $55.79 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $52.87 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $47.99 | 2022 | |
| Acorda Therapeutics, INC | $41.69 | 2019-2021 | |
| Argenx US, INC. | $40.40 | 2022 | |
| Horizon Therapeutics Plc | $29.96 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $21.13 | 2021 | |
| Vertical Pharmaceuticals, LLC | $19.97 | 2019 | |
| Novo Nordisk INC | $17.63 | 2024 | Rybelsus |
| Impel Pharmaceuticals INC. | $17.15 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $16.16 | 2022 | |
| Ibsa Pharma INC. | $13.77 | 2020 | |
| Sk Life Science, INC. | $12.83 | 2021 | |
| Lupin INC. | $12.16 | 2020 | |
| Amneal Pharmaceuticals LLC | $11.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jubran Hoche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.